Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > Rufloxacin

Rufloxacin

Rufloxacin structure

Rufloxacin 

structure
  • CAS No:

    101363-10-4

  • Formula:

    C17H18FN3O3S

  • Chemical Name:

    Rufloxacin

  • Synonyms:

    7H-Pyrido[1,2,3-de]-1,4-benzothiazine-6-carboxylic acid,9-fluoro-2,3-dihydro-10-(4-methyl-1-piperazinyl)-7-oxo-;9-Fluoro-2,3-dihydro-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzothiazine-6-carboxylic acid;Rufloxacin

  • Categories:

    Active Pharmaceutical Ingredients  >  Synthetic Anti-infective Drugs

Description

Rufloxacin is a member of quinolines, a quinolone antibiotic and a fluoroquinolone antibiotic.|Rufloxacin is a quinolone antibiotic.

Rufloxacin Basic Attributes

363.41

363.41

Y521XM2900

759835

DTXSID6048412

J - Antiinfectives for systemic use

Characteristics

89.4

1.69920

1.54

574.6±50.0 °C(Predicted)

301.3ºC

Safety Information

|Warning|H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]|P261, P264, P270, P271, P280, P301+P312, P302+P352, P304+P340, P305+P351+P338, P312, P321, P330, P332+P313, P337+P313, P362, P403+P233, P405, and P501|The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

Drug Information

Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)

9-fluoro-10-(N-(4'-methyl)piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido(1,2,3de)-1,4-benzothiazine-6-carboxylic acid

Rufloxacin Use and Manufacturing

A tricyclic fluoroquinolone formulated as the hydrochloride salt. It is inactive against Gram-positive cocci with MICs >2 mg/L. It displays weak activity in vitro against Enterobacteriaceae with the MIC for most species >1 mg/L. Activity against Ps. aeruginosa is poor (MIC 16–32 mg/L). After loading doses of 400 and 600 mg followed with 9 days of either 200 or 300 mg, mean peak plasma levels were around 4.5–7 mg/L, respectively. The mean apparent elimination halflife was 44 h. Approximately 50%

Computed Properties

Molecular Weight:363.4
XLogP3:-0.3
Hydrogen Bond Donor Count:1
Hydrogen Bond Acceptor Count:8
Rotatable Bond Count:2
Exact Mass:363.10529078
Monoisotopic Mass:363.10529078
Topological Polar Surface Area:89.4
Heavy Atom Count:25
Complexity:608
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes

Recommended Suppliers of Rufloxacin

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.